Potency of Tecoma Stans Flowers on Atherothrombosis (in Vitro)

Issue

Vol. 8 No. 2 (2020): 2020 Volume 8- Issue -2

Date Log

Published
August 15, 2020

Potency of Tecoma Stans Flowers on Atherothrombosis (in Vitro)

https://doi.org/10.61096/ijamscr.v8.iss2.2020.150-154
Mr.S.Kameshwaran.,M.Pharm.,(Ph.D),
Department of Pharmacology, Excel College of Pharmacy, Pallakapalayam, Komarapalayam (Tk), Namakkal(Dt) Tamilnadu, India.

Corresponding Author(s) : Mr.S.Kameshwaran.,M.Pharm.,(Ph.D),

kamesh.pharm@gmail.com

International Journal of Allied Medical Sciences and Clinical Research, Vol. 8 No. 2 (2020): 2020 Volume 8- Issue -2

Abstract

Tecoma stans and Phytol (PHY) are evident in different test systems because of their positive biological results. This research tests anti-atherothrombosis activity of the Tecoma stans (EETS) and Phytol (PHY) ethanolic extract. The EETS and/or PHY clotlysis activity was investigated by taking Streptokinase (SK) as a normal drug used for clotlysis. The findings indicate that the EETS and PHY showed concentration-dependent clotlysis activity in coagulated human bloodThe EETS and PHY's maximum clotlysis was observed at 62.42 ± 1.14 percent and 55.04 ± 0.24 percent, respectively with 80 ?g and 150 ?g per pipeline. The EETS co-treated with PHY showed greater potential for clotlysis than the EETS and PHY. The vehicle displayed marginal clotlysis efficiency (3.49 ± 2.51 percent) while the regular SK (100 I.U.) demonstrated clotlysis activity at 76.54 ±2.23 percent. The EETS and/or PHY demonstrated in vitro clotlysis behavior in human coagulated blood.

Keywords

Tecoma stans Streptokinase Antioxidant Atherothrombosis Phytol
1.
Mr.S.Kameshwaran.,M.Pharm.,(Ph.D),. Potency of Tecoma Stans Flowers on Atherothrombosis (in Vitro). Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2020 Aug. 15 [cited 2026 Apr. 16];8(2):150-4. Available from: https://ijamscr.com/ijamscr/article/view/842
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J, 25(14), 2004, 1197-207.
  2. . Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Texas Heart Institute J, 34(3), 2007, 318-27.
  3. . Jankun J, Skrzypczak-Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys, 17(1-2), 1999, 109-23.
  4. . KNV Rao. Establishment of two varieties in Tecoma stans of indian origin pharmacognostically and pharmacologically. Journal of Phytology, 2, 2010, 92-102.
  5. . Islam MT, Khan MR, Mishra SK. An updated literature-based review: phytochemistry, pharmacology and therapeutic promises of Nigella sativa L. Orient Pharm Exp Med, 2019, 1-5. doi: 10.1007/s13596-019-00363-3.
  6. . Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Daginawala HF. Development of an in vitro model to study clot lysis activity of thrombolytic drugs. Thromb J, 4(1), 2006, 14.
  7. . Torres N, Guevara-Cruz M, Velázquez-Villegas LA, Tovar AR. Nutrition and Atherosclerosis. Arch Med Res, 46(5), 2015, 408-26.
  8. . Aggarwal BB. Molecular Targets and Therapeutic Uses of Spices. Google Books. 259, 2009. ISBN: 978-981-4468-95-4.
  9. . Islam MT, Alencar MVOB, Machado KC, Machado KC, Melo-Cavalcante AAC, Sousa DP, et al. Phytol in a pharma-medico-stance. Chem Biol Interact, 240, 2015, 60-73.
  10. . Al-Naqeep G, Al-Zubairi AS, Ismail M, Amom ZH, Esa NM. Antiatherogenic Potential of Nigella sativa Seeds and Oil in Diet-Induced Hypercholesterolemia in Rabbits. Evid Based Complement Alternat Med, 2011, 213628.
  11. . Gonca E, Kurt Ç. Cardioprotective effect of Thymoquinone: a constituent of Nigella sativa L., against myocardial ischemia/reperfusion injury and ventricular arrhythmias in anaesthetized rats. Pak J Pharm Sci, 28(4), 2015, 1267-73.
  12. . Leys D. Atherothrombosis: a major health burden. Cerebrovasc Dis. 11(2), 2017, 1-4.
  13. . Falzon CC, Balabanova A. Phytotherapy: an Introduction to Herbal Medicine. Prim Care, 44(2), 2017, 217-27.
  14. . Kelber O, Bauer R, Kubelka W. Phytotherapy in Functional Gastrointestinal Disorders. Dig Dis, 35(S1), 2017, 36-42.
  15. Kameshwaran S et al / Int. J. of Allied Med. Sci. and Clin. Research Vol-8(2) 2020 [150-154]
  17. . Tsui PF, Lin CS, Ho LJ, Lai JH. Spices and Atherosclerosis. Nutrients, 10(11), 2018, 1724.
  18. . Wu T, Peng Y, Yan S, Li N, Chen Y, Lan T. Andrographolide Ameliorates Atherosclerosis by Suppressing Pro-Inflammation and ROS Generation- Mediated Foam Cell Formation. Inflammation, 41(5), 2018, 1681-9.
  19. . Li T, Wang W, Li YX, Li X, Ji WJ, Ma YQ, et al. Pseudolaric acid B attenuates atherosclerosis progression and inflammation by suppressing PPARγ- mediated NF-κB activation. Int Immunopharmacol, 59, 2018, 76-85.
  20. . Elkady AI, Hussein RA, El-Assouli SM. Mechanism of Action of Nigella sativa on Human Colon Cancer Cells: the Suppression of AP-1 and NF-κB Transcription Factors and the Induction of Cytoprotective Genes. Asian Pac J Cancer Prev, 16(17), 2015, 7943-57.
  21. . Majdalawieh AF, Fayyad MW, Nasrallah GK. Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa. Crit Rev Food Sci Nutr, 57(18), 2017, 3911-28.
  22. . An JY, Jheng HF, Nagai H, Sanada K, Takahashi H, Iwase M, et al. A Phytol- Enriched Diet Activates PPAR-α in the Liver and Brown Adipose Tissue to Ameliorate Obesity-Induced Metabolic Abnormalities. Mol Nutr Food Res, 62(6), 2018, e1700688.
  23. . Orekhov AN, Grechko AV, Romanenko EB, Zhang D, Chistiakov DA. Novel approaches to anti-atherosclerotic therapy: Cell-based models and herbal preparations (Review of our own data). Curr Drug Discov Technol, 2018.
Read More
Author biographies is not available.
Statistic
Read Counter : 181 Download : 453